Sulfasalazine
(Synonyms: 柳氮磺吡啶; NSC 667219) 目录号 : GC16868
Sulfasalazine是一种磺胺类药物。
Cas No.:599-79-1
Sample solution is provided at 25 µL, 10mM.
Sulfasalazine is a sulfonamide drug [1]. Sulfasalazine can inhibit the NF-κB pathway and reduce cytokine release, thereby regulating immune responses [2]. Sulfasalazine is commonly used to treat inflammatory bowel disease and rheumatoid arthritis [3-4].
In Jurkat T-lymphocytes, Sulfasalazine (0.2mM, 0.5mM, 1mM, 2mM; 24h) induces cell apoptosis [5]. In endothelial cells, Sulfasalazine (0.125mM, 24h) inhibits tritiated thymidine incorporation and cell proliferation [6]. In RBL5 cells, Sulfasalazine (1.25mM, 24h) inhibits NF-κB/Rel activation in mouse T lymphocytes [7].
In ICR mice, Sulfasalazine (250mg/kg, 500mg/kg, 1000mg/kg; po; 4 weeks) significantly increased serum levels of ALT, ALP and TBIL [8]. In DSS-Induced ulcerative colitis mice, Sulfasalazine (30mg/kg, 60mg/kg; ip; 7d) can inhibit colon length and mucosal inflammatory infiltration [9]. In middle cerebral artery occlusion mice, Sulfasalazine (5mg/kg, 10mg/kg; iv; single injection) could reduce the infarct size and improve neuro-motor function [10].
References:
[1]. Goldman P, Peppercorn MA. Sulfasalazine. New England Journal of Medicine. 1975 Jul 3; 293(1): 20-23.
[2]. Wahl C, Liptay S, Adler G, et al. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. The Journal of clinical investigation. 1998 Mar 1; 101(5): 1163-1174.
[3]. Peppercorn MA. Sulfasalazine: pharmacology, clinical use, toxicity, and related new drug development. Annals of Internal Medicine. 1984 Sep 1; 101(3): 377-386.
[4]. Plosker GL, Croom KF. Sulfasalazine: a review of its use in the management of rheumatoid arthritis. Drugs. 2005 Sep; 65: 1825-1849.
[5]. Liptay S, Fulda S, Schanbacher M, et al. Molecular mechanisms of sulfasalazine‐induced T‐cell apoptosis. British Journal of Pharmacology. 2002 Nov; 137(5): 608-620.
[6]. Sharon P, Drab EA, Linder JS, et al. The effect of sulfasalazine on bovine endothelial cell proliferation and cell cycle phase distribution: comparison with olsalazine, 5-aminosalicylic acid, and sulfapyridine. The Journal of laboratory and clinical medicine. 1992 Jan 1; 119(1): 99-107.
[7]. Liptay S, Bachem M, Hacker G, et al. Inhibition of nuclear factor kappa B and induction of apoptosis in T‐lymphocytes by sulfasalazine. British journal of pharmacology. 1999 Dec; 128(7): 1361-1369.
[8]. Li YC, Shen JD, Lu SF, et al. Transcriptomic analysis reveals the mechanism of sulfasalazine-induced liver injury in mice. Toxicology Letters. 2020 Mar 15; 321: 12-20.
[9]. Shin MR, Kim KJ, Kim SH, et al. Comparative Evaluation between Sulfasalazine Alone and in Combination with Herbal Medicine on DSS‐Induced Ulcerative Colitis Mice. BioMed Research International. 2017; 2017(1): 6742652.
[10]. Li X, Ding H, Jing J, et al. Sulfasalazine improves neuronal function in mice with ischemic stroke by inhibiting the STING/NF-κB pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2025 May; 398(5): 5797-5810.
Sulfasalazine是一种磺胺类药物 [1]。Sulfasalazine可以抑制NF-κB通路并减少细胞因子释放，从而调节免疫反应 [2]。Sulfasalazine常用于治疗炎症性肠病和类风湿性关节炎 [3-4]。
在Jurkat T淋巴细胞中，Sulfasalazine（0.2mM、0.5mM、1mM、2mM；24h）诱导细胞凋亡 [5]。在内皮细胞中，Sulfasalazine（0.125mM；24h）抑制氚化胸苷的掺入和细胞增殖 [6]。在RBL5细胞中，Sulfasalazine（1.25mM；24h）抑制小鼠T淋巴细胞中的NF-κB/Rel活化 [7]。
在ICR小鼠中，Sulfasalazine（250mg/kg、500mg/kg、1000mg/kg；po；4周）显著升高血清ALT、ALP和TBIL水平 [8]。在DSS诱发的溃疡性结肠炎小鼠中，Sulfasalazine（30mg/kg、60mg/kg；ip；7d）可抑制结肠长度和粘膜炎症浸润 [9]。在大脑中动脉闭塞小鼠中，Sulfasalazine（5mg/kg、10mg/kg；iv；单次注射）可缩小梗死面积并改善神经运动功能 [10]。
| Cell experiment [1]: | |
Cell lines | Jurkat T-lymphocytes |
Preparation Method | Jurkat T-lymphocytes were grown under standard conditions in RPMI 1640 medium supplemented with 100U/mL penicillin, 100μg/mL streptomycin, 2mM glutamine, and 10% FCS. Sulfasalazine was freshly dissolved in the medium and added to the culture at the indicated concentrations and times. |
Reaction Conditions | 0.2mM, 0.5mM, 1mM, 2mM; 24h |
Applications | Sulfasalazine induces apoptosis in human Jurkat T-lymphocytes. |
| Animal experiment [2]: | |
Animal models | ICR mice |
Preparation Method | Forty ICR mice were randomly divided into four experimental groups (n = 10): control group and Sulfasalazine (SASP) groups (250mg/kg, 500mg/kg, 1000mg/kg). SASP (98% of purity) was dissolved in 0.1% dimethyl sulfoxide (DMSO) and were administered by oral gavage in a volume of 10mL/kg for 4 weeks. Control group received equal volume of 0.1% DMSO. |
Dosage form | 250mg/kg, 500mg/kg, 1000mg/kg; po; 4 weeks |
Applications | Sulfasalazine significantly increased serum levels of ALT, ALP and TBIL. |
References: | |
| Cas No. | 599-79-1 | SDF | |
| 别名 | 柳氮磺吡啶; NSC 667219 | ||
| 化学名 | (3Z)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid | ||
| Canonical SMILES | C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)NN=C3C=CC(=O)C(=C3)C(=O)O | ||
| 分子式 | C18H14N4O5S | 分子量 | 398.39 |
| 溶解度 | ≥ 17.7 mg/mL in DMSO | 储存条件 | Store at RT |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5101 mL | 12.5505 mL | 25.101 mL |
| 5 mM | 0.502 mL | 2.5101 mL | 5.0202 mL |
| 10 mM | 0.251 mL | 1.2551 mL | 2.5101 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet